Forum Topic News
  • Conversation: Potential applications & Growth of Dermatomyositis Drug Market in Pharmaceutical Industry

    • February 14, 2018 11:13 AM GMT
      • Post(s)
        548

      Potential applications & Growth of Dermatomyositis Drug Market in Pharmaceutical Industry

      NEW YORK, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Dermatomyositis (DM) is an idiopathic (disease for which cause is unknown) inflammatory disorder of skin and skeletal muscle involvement. Patients with skeletal muscle involvement have polymyositis (PM), and patients without muscle damage and typical skin lesions have amyopathic dermatomyositis. Scleromyositis is overlap syndrome associated with anti-PM-Sci antibodies. Dermatomyositis (DM) can be treated with variety of drugs few of them are:
      Abatacept – It is also known as Orencia is a protein that prevents body’s immune system from attacking healthy tissues such as joints. It is a prescription medicine used to treat the symptoms of rheumatoid arthritis, also prevent joint damage caused by rheumatoid arthritis.
      Baricitinib – It is an oral selective JAK1 and JAK2 inhibitor used in the treatment of rheumatoid arthritis.
      Dalazatide – It is formerly known as ShK-186 is a investigational drug designed to selectively target cells that cause autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.
      Get complete access of this report: https://www.profsharemarketresearch.com/dermatomyositis-drug-market-report/
      Read more: http://bit.ly/2ClMA8E

Add Reputation

Do you want to add reputation for this member by this post?

or cancel